logo

HITAP เข้าสู่ระบบ

ลืมรหัสผ่าน?

Cost-utility analysis of adjuvant therapy for stage III colon cancer in Thailand

Home > Research Projects > Strategy 3 : HTA Research > Cost-utility analysis of adjuvant therapy for stage III colon cancer in Thailand

Project Code

01-328-2551

Research team

Researchers

Panattharin Lerdkiattikorn, M.Sc. (Pharm.)

Co - Researcher

-

Project Details

Strategies
Category
Support
Tags
Project duration

Start: 15 October 2008
End: 15 October 2014

Contact
[email protected]

Project Status

Completed - 100%

Viewer: 1391

Publish date11 December 2011 12:35

Project Summary

The objective of this study is to analyze the impact on the national budget of Chemotherapy as adjuvant therapy. The costeffectiveness and cost-utility of providing adjuvant therapy for stage III colorectal cancer patients were estimated. The regimens with and without Oxaliplatin for stage III colorectal cancer patients were compared. The 5-Fluorouracil based regimen was 5-Fluorouracil/ Leucovorin, the Fluoropyrimidines based regimen were Capecitabine monotherapy and Capecitabine/Oxaliplatin (XELOX Regimen), and Platinum based regimen is 5-Fluorouracil/leucovorin/oxaliplatin (FOLFOX).  

Documents

Activity

โครงการประเมินเทคโนโลยีและนโยบายด้านสุขภาพ ชั้น 6 อาคาร 6 กรมอนามัย กระทรวงสาธารณสุข ถ.ติวานนท์ อ.เมือง จ.นนทบุรี 11000

โทร : +662-590-4549 , +662-590-4374-5
โทรสาร : +662-590-4369
E-mail : [email protected]

© Copyright - HITAP 2014
Top